Profile of Oritavancin and its potential in the treatment of acute bacterial skin structure infections

Infection and Drug Resistance

Volumn 8, Issue , 2015, Pages 189-197

  Mitra, Subhashis ^a   Saeed, Usman ^a   Havlichek, Daniel H ^a   Stein, Gary E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Antibiotic; Gram positive bacteria; MIC; MRSA; Vancomycin; VRSA

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ORITAVANCIN; VANCOMYCIN;

ABSCESS; ACUTE BACTERIAL SKIN AND SKIN STRUCTURE; ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERIAL SKIN DISEASE; BACTERICIDAL ACTIVITY; CELLULITIS; CHILL; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIARRHEA; DISEASE MODEL; DIZZINESS; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; FATIGUE; FEVER; GROWTH INHIBITION; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; INJECTION SITE EXTRAVASATION; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; INSOMNIA; LIMB ABSCESS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; URTICARIA; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

EID: 84982273193     PISSN: None     EISSN: 11786973     Source Type: Journal    
DOI: 10.2147/IDR.S69412     Document Type: Review

References (37)

1. Edelsberg J, Weycker D, Barron R, et al. Prevalence of antibiotic resistance in us hospitals. Diagn Microbiol Infect Dis. 2014;78:255-262.
2. Oritavancin (orbactiv) for skin and skin structure infections. Med Lett Drugs Ther. 2015;57:3-5.
3. ORBACTIV™ (Oritavancin) For Injection. Parsippany, NJ: The Medicines Company; 2014. [Prescribing Information].
4. Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis. 2012;54(Suppl 3):S214-S219.
5. Groves P, Searle MS, Mackay JP, Williams DH. The structure of an asymmetric dimer relevant to the mode of action of the glycopeptide antibiotics. Structure. 1994;2:747-754.
6. Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev. 2003;26:511-532.
7. Belley A, Neesham-Grenon E, McKay G, et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother. 2009;53:918-925.
8. Belley A, Neesham-Grenon E, Arhin FF, McKay GA, Parr TR Jr, Moeck G. Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52: 3820-3822.
9. Belley A, McKay GA, Arhin FF, et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother. 2010;54:5369-5371.
10. Baquir B, Lemaire S, Van Bambeke F, Tulkens PM, Lin L, Spellberg B. Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin. Clin Infect Dis. 2012;54(Suppl 3):S229-S232.
11. Citron DM, Kwok YY, Appleman MD. In vitro activity of oritavancin (ly333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic gram-positive cocci. Anaerobe. 2005;11:93-95.
12. Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN. Activity of oritavancin against gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and us hospitals (2010-2013). J Antimicrob Chemother. 2015;70:498-504.
13. Karlowsky JA, Walkty AJ, Baxter MR, Adam HJ, Zhanel GG. In vitro activity of oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013. Diagn Microbiol Infect Dis. 2014;80:311-315.
14. Arhin FF, Sarmiento I, Belley A, et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother. 2008;52:1597-1603.
15. Patti GJ, Kim SJ, Yu TY, et al. Vancomycin and oritavancin have different modes of action in enterococcus faecium. J Mol Biol. 2009;392: 1178-1191.
16. Arthur M, Depardieu F, Reynolds P, Courvalin P. Moderate-level resistance to glycopeptide ly333328 mediated by genes of the VanA and VanB clusters in enterococci. Antimicrob Agents Chemother. 1999;43: 1875-1880.
17. Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollam JS, Forrest A. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother. 2009;53: 4422-4428.
18. Ambrose PG, Drusano GL, Craig WA. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis. 2012;54(Suppl 3):S220-S228.
19. Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis. 2004;50:95-102.
20. Fetterly GJ, Ong CM, Bhavnani SM, et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother. 2005;49:148-152.
21. Boylan CJ, Campanale K, Iversen PW, Phillips DL, Zeckel ML, Parr TR Jr. Pharmacodynamics of oritavancin (ly333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother. 2003;47:1700-1706.
22. Rupp ME, Fey PD, Longo GM. Effect of ly333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model. J Antimicrob Chemother. 2001;47:705-707.
23. Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, Mercier RC, Rybak MJ. Efficacy of ly333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1998;42:981-983.
24. Saleh-Mghir A, Lefort A, Petegnief Y, et al. Activity and diffusion of ly333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother. 1999;43: 115-120.
25. Lefort A, Saleh-Mghir A, Garry L, Carbon C, Fantin B. Activity of ly333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Antimicrob Agents Chemother. 2000;44:3017-3021.
26. Gerber J, Smirnov A, Wellmer A, et al. Activity of ly333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob Agents Chemother. 2001;45: 2169-2172.
27. Cabellos C, Fernàndez A, Maiques JM, et al. Experimental study of ly333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother. 2003;47:1907-1911.
28. Freeman J, Marquis M, Crowther GS, et al. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model. J Antimicrob Chemother. 2012;67:2919-2926.
29. Heine HS, Bassett J, Miller L, et al. Efficacy of oritavancin in a murine model of bacillus anthracis spore inhalation anthrax. Antimicrob Agents Chemother. 2008;52:3350-3357.
30. Allen NE. From vancomycin to oritavancin: the discovery and development of a novel lipoglycopeptide antibiotic. Anti Infect Agents Med Chem. 2010;9:23-47.
31. Corey GR, Kabler H, Mehra P, et al; SOLO I Investigators. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370:2180-2190.
32. Corey GR, Good S, Jiang H, et al; SOLO II Investigators. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60:254-262.
33. Talan DA, Krishnadasan A, Gorwitz RJ, et al; EMERGEncy ID Net Study Group. Comparison of Staphylococcus aureus from skin and soft-tissue infections in us emergency department patients, 2004 and 2008. Clin Infect Dis. 2011;53:144-149.
34. Moran GJ, Krishnadasan A, Gorwitz RJ, et al; EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666-674.
35. Singer AJ, Talan DA. Management of skin abscesses in the era of methicillin-resistant Staphylococcus aureus. N Engl J Med. 2014;370: 1039-1047.
36. Tice AD, Rehm SJ. Meeting the challenges of methicillin-resistant Staphylococcus aureus with outpatient parenteral antimicrobial therapy. Clin Infect Dis. 2010;51(Suppl 2):S171-S175.
37. Tice A. Oritavancin: a new opportunity for outpatient therapy of serious infections. Clin Infect Dis. 2012;54(Suppl 3):S239-S243.